Intermediate for Ibrutinib. Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.


Product Name:                  (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine

Synonyms:                         N/A

CAS Number:                     1022150-12-4

Molecular Weight:            386.4554

Molecular Formula:          C22H22N6O

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               Nc1ncnc2c1c(nn2[C@@H]1CCCNC1)c1ccc(cc1)Oc1ccccc1

  • $208.00
  • Ex Tax: $208.00

Available Options